Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
The cuts will mostly affect the TAPI division in Israel and will roll out over the next two years.
read more
The regimen treats virologically-suppressed patients who have switched from Biktarvy.
read more
The drugmaker will advance elecoglipron into an extensive phase 3 program in obesity and type 2 diabetes.
read more
While the board searches for a permanent successor, Albert Manzone will act as interim president and CEO.
read more
Navacaprant failed to lead to improvement compared to a placebo.
read more
Complicated urinary tract infections have historically required IV treatment when standard oral options fail.
read more
The acquisition gives Lilly a pipeline of orally-available MNK inhibitors for treating chronic pain.
read more
DT120 is a lysergamide compound — an LSD derivative — administered as a single 100 µg orally disintegrating tablet.
read more
The company's proprietary drug delivery platform replaces daily pills with a once-monthly capsule that releases a stable dose.
read more
The phase 1b/2 trial will be the first time that an eIF2B is administered to people with VWM disease.
read more
Centanafadine was granted Priority Review and has a PDUFA target action date of July 24, 2026.
read more
The company is adding leading brands to its portfolio to boost its position in Belgium, Poland, and the Nordics.
read more
The retraction comes amid increasing regulatory scrutiny of the drug.
read more
The phase 1/2 study will evaluate the combo in EGFR-mutated and PD-L1 positive locally advanced or metastatic NSCLC.
read more
If approved, deucrictibant will be the first oral bradykinin B2 receptor antagonist to treat HAE attacks.
read more